SCM
NAUT icon

Suvretta Capital Management’s Nautilus Biotechnolgy NAUT Stock Holding History

Suvretta Capital Management’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-314,835
Closed -$1.93M – 107
2021
Q3 		$1.93M Hold
314,835
– – 0.03% 96
2021
Q2 		$3.18M Buy
314,835
+300,000
+2,022% +$3.25M 0.05% 101
2021
Q1 		$204K Sell
14,835
-285,165
-95% -$3.95M ﹤0.01% 103
2020
Q4 		$3.25M Hold
300,000
– – 0.05% 85
2020
Q3 		$3.25M Buy
+300,000
New +$3.2M 0.06% 73

Other funds holding NAUT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
AEPBI
AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.01B AUM 2.93% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Suvretta Capital Management's NAUT Position: Q4 2021 in Review

Suvretta Capital Management sold out of Nautilus Biotechnolgy (NAUT) in Q4 2021, closing a stake of 314,835 shares — an estimated $1.93M sold.

Suvretta Capital Management first reported a position in NAUT in Q3 2020 and held it in 5 quarters. The position peaked at $3.25M in Q4 2020. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2021.

  • Suvretta Capital Management reported no remaining Nautilus Biotechnolgy position as of Q4 2021 after selling out during the quarter.
  • Suvretta Capital Management sold 314,835 Nautilus Biotechnolgy shares in Q4 2021, an estimated $1.93M.
  • Suvretta Capital Management first reported a position in Nautilus Biotechnolgy in Q3 2020 and held it in 5 quarters.
  • Suvretta Capital Management's Nautilus Biotechnolgy position peaked at $3.25M in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2021.

Based on Suvretta Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.